Endocrine disorders in Kearns-Sayre syndrome with different severity of symptoms: two case reports and a literature review

Submitted: 2 August 2024
Accepted: 23 September 2024
Published: 30 October 2024
Abstract Views: 738
PDF: 237
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Kearns-Sayre Syndrome (KSS) is a variant of mitochondrial disorder caused by a Mitochondrial Deoxyribonucleic Acid (mtDNA) deletion. Clinical manifestations of KSS can include different organ and system involvement. Different organ malfunctions, more often cardiac dysfunction, can lead to death. No effective treatment of this condition exists to date. Here, we report two patients with KSS. Female patient with a large-scale deletion of 7,020 base pairs (bp) suffered from hypogonadism, diabetes mellitus with fluctuating glucose levels, and had poor general health. A male patient with a common 4,977 bp deletion did not have diabetes mellitus but had impaired glucose tolerance. He also had a higher level of general health than our female patient. Both patients had reduced Bone Mineral Density (BMD). In female patients, calcium and vitamin D supplementation combined with metabolic therapy and nutritional drink supplements helped increase BMD (up to 32% in L1-L4). Comparing these two patients suggests that the larger the mtDNA deletion is, the more severe the course of the disease is. Not only does the size of the mtDNA deletion probably determine the severity of the disease, but also such factors as mtDNA heteroplasmy level, presence of mtDNA duplications, and pleioplasmy. Moreover, continuous nonconsecutive metabolic therapy and nutritional supplements are helpful in the prevention of deterioration of symptoms and general health.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

de Laat P, Rodenburg R, Smeitink J. Mitochondrial Oxidative Phosphorylation Disorders. In: Blau N, Duran M, Gibson K, Dionisi Vici C (eds) Physician's Guide to the Diagnosis, Treatment, and Follow-Up of Inherited Metabolic Diseases. Springer, Berlin, Heidelberg. Part IV, Chapter 17, Mitochondrial Oxidative Phosphorylation Disorders by Paul de Laat, Richard Rodenburg, and Jan Smeitink; 2014. pp 337–359 DOI: https://doi.org/10.1007/978-3-642-40337-8_22
Schon EA, Rizzuto R, Moraes CT, et al. A direct repeat is a hotspot for large-scale deletion of human mitochondrial DNA. Science 1989;244:346-9. DOI: https://doi.org/10.1126/science.2711184
Samuels DC, Schon EA, Chinnery PF. Two direct repeats cause most human mtDNA deletions. Trends Genet 2004;20:393-8. DOI: https://doi.org/10.1016/j.tig.2004.07.003
DiMauro S, Schon EA. Mitochondrial disorders in the nervous system. Annu Rev Neurosci 2008;31:91-123. DOI: https://doi.org/10.1146/annurev.neuro.30.051606.094302
Suomalainen A, Kaukonen J. Diseases caused by nuclear genes affecting mtDNA stability. Am J Med Genet 2001;106:53-61. DOI: https://doi.org/10.1002/ajmg.1379
Harvey JN, Barnett D. Endocrine dysfunction in Kearns-Sayre syndrome. Clin Endocrinol (Oxf) 1992;37:97-103. DOI: https://doi.org/10.1111/j.1365-2265.1992.tb02289.x
De Block CE, De Leeuw IH, Maassen JA, et al. A novel 7301-bp deletion in mitochondrial DNA in a patient with Kearns-Sayre syndrome, diabetes mellitus, and primary amenorrhoea. Exp Clin Endocrinol Diabetes 2004;112:80-3. DOI: https://doi.org/10.1055/s-2004-815754
Khambatta S, Nguyen DL, Beckman TJ, Wittich CM. Kearns-Sayre syndrome: a case series of 35 adults and children. Int J Gen Med 2014;7:325-32. DOI: https://doi.org/10.2147/IJGM.S65560
Romo L, Gold NB, Walker MA. Endocrine features of primary mitochondrial diseases. Curr Opin Endocrinol Diabetes Obes 2024;31:34-42. DOI: https://doi.org/10.1097/MED.0000000000000848
Ng YS, Lim AZ, Panagiotou G, Turnbull DM, Walker M. Endocrine Manifestations and New Developments in Mitochondrial Disease. Endocr Rev 2022;43:583-609. DOI: https://doi.org/10.1210/endrev/bnab036
Quintos JB, Hodax JK, Gonzales-Ellis BA, et al. Efficacy of growth hormone therapy in Kearns-Sayre syndrome: the KIGS experience. J Pediatr Endocrinol Metab 2016;29:1319-24. DOI: https://doi.org/10.1515/jpem-2016-0172
Lempereur L, Brambilla D, Scoto GM, et al. Growth hormone protects human lymphocytes from irradiation-induced cell death. Br J Pharmacol 2003;138:1411-6. DOI: https://doi.org/10.1038/sj.bjp.0705173
Romano S, Samara D, Crosnier H, et al. Variable outcome of growth hormone administration in respiratory chain deficiency. Mol Genet Metab 2008;93:195-9. DOI: https://doi.org/10.1016/j.ymgme.2007.09.007
Obara-Moszynska M, Maceluch J, Bobkowski W, et al. A novel mitochondrial DNA deletion in a patient with Kearns-Sayre syndrome: a late-onset of the fatal cardiac conduction deficit and cardiomyopathy accompanying long-term rGH treatment. BMC Pediatr 2013;13:27. DOI: https://doi.org/10.1186/1471-2431-13-27
Gandhi SS, Muraresku C, McCormick EM, et al. Risk factors for poor bone health in primary mitochondrial disease. J Inherit Metab Dis 2017;40:673-83. DOI: https://doi.org/10.1007/s10545-017-0046-2
Reinauer C, Meissner T, Roden M, et al. Low prevalence of patients with mitochondrial disease in the German/Austrian DPV diabetes registry. Eur J Pediatr 2016;175:613-22. DOI: https://doi.org/10.1007/s00431-015-2675-5
Papadakis JL, Anderson LM, Garza K, et al. Psychosocial aspects of diabetes technology use: the child and family perspective. Endocrinol Metab Clin North Am 2020;49:127-41. DOI: https://doi.org/10.1016/j.ecl.2019.10.004
Isotani H, Fukumoto Y, Kawamura H, et al. Hypoparathyroidism and insulin-dependent diabetes mellitus in a patient with Kearns-Sayre syndrome harbouring a mitochondrial DNA deletion. Clin Endocrinol (Oxf) 1996;45:637-41. DOI: https://doi.org/10.1046/j.1365-2265.1996.00856.x
Gloria Pang SW, Chih Lee HH, Ng Wing Kei C, et al. Kearns-Sayre Syndrome Minus: Two Cases of Identical Large-Scale Mitochondrial DNA Deletions with Presentations outside the Classical Triad. Case Rep Genet 2022;2022:4153357. DOI: https://doi.org/10.1155/2022/4153357
Artuch R, Pavía C, Playán A, et al. Multiple endocrine involvement in two pediatric patients with Kearns-Sayre syndrome. Horm Res 1998;50:99-104. DOI: https://doi.org/10.1159/000023243
Poulton J, O'Rahilly S, Morten KJ, Clark A. Mitochondrial DNA, diabetes and pancreatic pathology in Kearns-Sayre syndrome. Diabetologia 1995;38:868-71. DOI: https://doi.org/10.1007/s001250050366
Alcolado JC, Majid A, Brockington M, Sweeney MG, Morgan R, Rees A, Harding AE, Barnett AH. Mitochondrial gene defects in patients with NIDDM. Diabetologia 1994;37:372-6. DOI: https://doi.org/10.1007/s001250050119
Kishimoto M, Hashiramoto M, Araki S, et al. Diabetes mellitus carrying a mutation in the mitochondrial tRNA(Leu(UUR)) gene. Diabetologia 1995;38:193-200. DOI: https://doi.org/10.1007/s001250050270
Berio A, Piazzi A. Multiple endocrinopathies (growth hormone deficiency, autoimmune hypothyroidism and diabetes mellitus) in Kearns-Sayre syndrome. Pediatr Med Chir 2013;35:137-40. DOI: https://doi.org/10.4081/pmc.2013.48

How to Cite

Amergoolov, I. I., Khruleva, Y. I., Pavlova, M. G., Likhodey, N. V., Sulaev, A. M., Surkova, E. V., Sych, Y. P., Kalashnikova, M. F., Arustamyan, A. S., Martirosyan, G. A., & Lew-Gor, S. T. (2024). Endocrine disorders in Kearns-Sayre syndrome with different severity of symptoms: two case reports and a literature review. European Journal of Translational Myology, 34(4). https://doi.org/10.4081/ejtm.2024.12897